Key Takeaways & Executive Findings
- •• Severely impaired diffusion capacity, combined respiratory failure, and elevated red blood cell distribution width are major risk factors for frequent hospitalizations in COPD patients. • Early identification and intervention of these risk factors can reduce hospitalization frequency and improve quality of life. • FEV1% predicted below 52.9%, DLCO below 4 mmol/(min·kPa), presence of type I respiratory failure, and RDW above 14.5% indicate increased risk of frequent hospitalizations. • The study highlights the importance of comprehensive assessment beyond traditional pulmonary function tests to predict disease progression and guide management.
Abstract
BACKGROUND: Understanding the characteristics of lung tissue repair and risk factors in patients with chronic obstructive pulmonary disease (COPD) is crucial for improving disease management and enhancing patient quality of life. Existing clinical indicators cannot accurately quantify the tissue repair potential and disease progression risk in patients with a history of frequent hospitalizations. OBJECTIVE: To conduct a risk prediction model analysis of lung tissue repair mechanisms in COPD based on computer simulation and case validation, thereby promoting lung tissue repair/regeneration in COPD patients, reducing the frequency of hospitalizations, and improving quality of life. METHODS: Medical records from 200 patients with COPD hospitalized at Beijing Jingmei Group General Hospital from 2022-10-01 to 2023-10-01 were collected. Patients were grouped based on the number of hospitalizations for COPD within 1 year after discharge: 100 patients with ≥2 hospitalizations were assigned to the frequent hospitalization group, and 100 patients with <2 hospitalizations were assigned to the non-frequent hospitalization group. General clinical data, pulmonary function, blood gas analysis, and hematological indicators were compared between the two groups. Variables with P < 0.05 were included in a multivariate logistic regression model to identify risk factors for rehospitalization within 1 year. The area under the receiver operating characteristic curve (AUC) was used to evaluate the predictive efficacy of the clinical risk factor model. RESULTS AND CONCLUSION: (1) Pulmonary function: There were significant differences between the two groups in FEV1% predicted, FVC, FVC% predicted, FEV1/FVC, residual volume/total lung capacity ratio, diffusing capacity of the lung for carbon monoxide (DLCO), and DLCO/alveolar volume (P < 0.05). (2) Blood gas analysis: Significant differences were found in oxygen partial pressure, carbon dioxide partial pressure, oxygen saturation, and respiratory failure type (P < 0.05). (3) Hematological indicators: Significant differences were observed in absolute neutrophil count, D-dimer, absolute lymphocyte count, neutrophil percentage, and red blood cell distribution width (RDW) (P < 0.05), while no significant differences were found in eosinophil percentage, fibrinogen, and absolute eosinophil count (P > 0.05). (4) Logistic regression analysis showed that FEV1% predicted (OR=1.01, 95%CI: 1.004-1.017, P=0.011), DLCO (OR=2.28, 95%CI: 1.270-3.025, P=0.004), type I respiratory failure (OR=3.15, 95%CI: 2.414-5.947, P=0.001), type II respiratory failure (OR=7.03, 95%CI: 1.688-8.604, P=0.001), and RDW (OR=1.50, 95%CI: 0.65-3.44, P < 0.0001) were risk factors for frequent hospitalizations in COPD patients. (5) ROC curve analysis showed that when FEV1% predicted was below 52.9%, DLCO below 4 mmol/(min·kPa), presence of type I respiratory failure, or RDW above 14.5%, the risk of frequent hospitalizations increased. (6) The logistic regression model and ROC curve analysis indicated that severely impaired diffusion capacity, combined respiratory failure, and elevated RDW are major risk factors for frequent hospitalizations in COPD patients. Early identification and intervention of these factors are important for improving lung tissue repair potential, predicting disease progression risk, and enhancing quality of life.
1. Introduction
Chronic obstructive pulmonary disease (COPD) severely affects patients' quality of life [1-2]. Its core pathological features are irreversible airflow limitation and progressive destruction of lung tissue, especially alveoli and airways. Traditional treatment mainly focuses on relieving symptoms, while promoting lung tissue repair/regeneration and reversing disease progression remain fundamental therapeutic challenges. Some studies have shown that even patients with relatively good pulmonary function may experience frequent hospitalizations, while others with severely impaired lung function may not have a history of frequent hospitalizations [3], suggesting that relying solely on pulmonary function tests to assess the severity of COPD may be incomplete.
The number of frequent hospitalizations in the past year is a risk factor for predicting future frequent hospitalization frequency in COPD patients [4]. For patients with frequent hospitalizations, closer monitoring and management are needed to reduce the risk of future hospitalizations. Long-term follow-up studies have shown that frequent hospitalizations in the first year are closely related to those in subsequent years [5], further emphasizing the importance of early diagnosis and treatment of COPD [6]. For those who have experienced two or more frequent hospitalizations in the past year, avoiding precipitating factors is crucial [7], which may include adjusting medication, enhancing pulmonary rehabilitation programs, vaccination, and other preventive measures [8-9].
Currently, most studies focus on differences between acute exacerbation and stable phases of COPD, while research on the mechanisms of lung tissue repair and risk prediction models for frequent hospitalizations is limited. This study aims to analyze the lung tissue repair mechanisms and risk factors in COPD patients using computer simulation and case validation, providing evidence for early intervention and improved management.
Loading authentic research manuscript (Pages 1–5)...
Chen Yanni, Chen Liang, Zhang Jianhong, Lu Zhenfang, Liu Min, Li Jian (2026). Lung tissue repair mechanisms and risk models for chronic obstructive pulmonary disease: an analysis based on computer simulation and experimental validation. Chinese Journal of Tissue Engineering Research. https://doi.org/10.12307/2026.21612
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What are the main risk factors for frequent hospitalizations in COPD patients?
The main risk factors identified in this study include severely impaired diffusion capacity (low DLCO), combined respiratory failure (type I or II), and elevated red blood cell distribution width (RDW). Additionally, lower FEV1% predicted was also a significant risk factor.
How can the risk of frequent hospitalizations be predicted in COPD patients?
The study developed a logistic regression model incorporating FEV1% predicted, DLCO, respiratory failure type, and RDW. The model showed good predictive performance, with specific cut-off values: FEV1% predicted < 52.9%, DLCO < 4 mmol/(min·kPa), presence of type I respiratory failure, and RDW > 14.5% indicate increased risk.
Why is diffusion capacity important in COPD?
Diffusion capacity reflects the ability of gas to transfer across the alveolar-capillary membrane. Severe impairment indicates poor gas exchange, leading to hypoxia and carbon dioxide retention, which can worsen the disease and increase hospitalization risk.
What is the significance of red blood cell distribution width (RDW) in COPD?
Elevated RDW may indicate underlying inflammation, oxidative stress, or nutritional deficiencies, which can affect red blood cell function and lead to anemia. In COPD, elevated RDW is associated with worse outcomes and increased hospitalization risk.
How can early intervention improve outcomes in COPD patients?
Early identification of risk factors such as impaired diffusion capacity, respiratory failure, and elevated RDW allows for targeted interventions like optimized oxygen therapy, ventilatory support, and management of comorbidities, which can reduce hospitalizations and improve quality of life.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.